Abstract Library

#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,

Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,

#1862 Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms

Introduction: Metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs) is associated with a more aggressive behaviour

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alexandraki K, Boutzios G, Nikolopoulos G, Tsoli M, Thomas D,

Keywords: bone disease,

#750 Management of Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor

Introduction: Nonfunctional NETs themselves present in generally two ways, either with symptoms caused by the tumor compression of other organs, or found by imaging test performed for other reasons.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Egorov A, Vasiliev I, Gurevich L, Kondrashin S, Parnova V,

Keywords: pancreas, nonfanctional tumor, metastase,